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In this Research Topic, Goyal and Haffty
have collected a series of papers on the
emerging field of cardio-oncology. Indeed,
Darby et al.’s paper demonstrating an
incremental 7% increase in risk of ischemic
events per gray increase in mean heart dose
has been a watershed moment in our efforts
to improve the therapeutic ratio of adju-
vant breast radiotherapy (1). While a 0.07
increase over baseline risk per Sievert may
seem high, it is important to understand
this relative increase in risk in the context
of the absolute baseline risk. Darby and col-
leagues do not provide a denominator for
eligible patients in the two population reg-
istries from which they drew their cases and
controls. Instead, they estimate the baseline
risk using data from 15 Western European
nations, and in Table S12 of the Supple-
mentary Material, go on to estimate the
absolute risk increase by age 80 years in
women exposed to RT at various ages and
with various co-morbid risk profiles. The
excess absolute risks appear to be modest
at first glance. For example, for a young
40-year-old woman receiving a high mean
heart dose of 10 Gy, the estimated absolute
excess risk of dying from cardiac disease
is about 1.4%. Should the same woman
have at least one co-morbid risk factor, her
excess risk is 2.3%. These numbers may
seem small, but are certainly relevant at the
population level, especially given that the
mortality benefit of adjuvant radiotherapy
is also modest (2). Current efforts at reduc-
ing the risks of incidental cardiac irradia-
tion have included advanced radiotherapy
techniques for cardiac avoidance such as
breath hold (3), gating treatments (4), pro-
ton therapy (5), prone positioning (6), and
combinations thereof such as respiratory
gating in the prone position (7).
Cardiac avoidance techniques are illus-
trative of the general potential that tech-
nological innovations can have on human
health. Going back to the very develop-
ment of megavoltage machines, improve-
ments in radiation delivery have consis-
tently improved the therapeutic ratio in
any number of settings. Recent reports have
demonstrated fewer late second malignan-
cies in children treated with proton ther-
apy (8), lower rates of desquamation in
breast cancer patients treated with IMRT
(9), higher rates of local control in lung
cancer patients treated with SBRT (10), and
improved biochemical control in patients
treated with highly conformal, high-dose
radiotherapy for prostate cancer (11). Sim-
ilar improvements in image-guided gyne-
cological brachytherapy (12), IMRT in
head/neck (13), GI (14), and gynecological
malignancies (15), as well as intracranial
SRS (16) have all demonstrated better out-
comes compared with control data. Even as
the calls for controlling costs become ever
more constant, it is important to remember
that the current excitement for a genom-
ically driven model of cancer care has
become possible only because of techno-
logical improvements in sequencing tech-
nologies. As such, continued funding, both
federal and private, for technology innova-
tions is critical and should not be relegated
to lower tiers of priority.
Coming back to breast cancer patients
and the cardiac risks they face from radio-
therapy, one additional (seemingly obvi-
ous) point needs to be made. While we can
invoke continually advancing technologies
for the purposes of cardiac avoidance (17),
sometimes a return to simpler solutions
may be all that is needed. Many women
with early-stage breast cancer are eligible
for off-protocol accelerated partial breast
irradiation as a standard of care option
(18). As one would expect, irradiating a
smaller volume of breast tissue leads to
lower incidental heart doses (19). Current
studies and protocols examining, for exam-
ple, breath hold parameters or prone posi-
tioning often include a large contingent
of women who are candidates for partial
breast irradiation. One rather elegant way
to avoid treating the heart is to simply not
treat it.
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